IGC Pharma, Inc. (IGC) is a Biotechnology company in the Healthcare sector, currently trading at $0.31. It has a SharesGrow Score of 58/100, indicating a above average investment profile with 4 out of 7 criteria passed.
Valuation: IGC trades at a trailing Price-to-Earnings (P/E) of -5.3 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.95.
Financials: revenue is $1M, +57.2%/yr average growth. Net income is $7M (loss), growing at +18.5%/yr. Net profit margin is -560.3% (negative). Gross margin is 48.7% (-0.2 pp trend).
Balance sheet: total debt is $238,000 against $6M equity (Debt-to-Equity (D/E) ratio 0.04, conservative). Current ratio is 1.28 (adequate). Debt-to-assets is 2.7%. Total assets: $9M.
Analyst outlook: 2 / 2 analysts rate IGC as buy (100%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 90/100 (Pass), Growth 90/100 (Pass), Past 0/100 (Fail), Health 75/100 (Pass), Moat 39/100 (Fail), Future 100/100 (Pass), Income 10/100 (Fail).
